Radiation-induced KRAS G12V mutant lung adenocarcinoma in a never smoker

Research output: Contribution to journalArticle

Abstract

The molecular profile of radiation-induced cancers remains poorly understood. This case report describes a 59-year-old male never smoker with a distant history of Hodgkin's lymphoma treated with mantle radiation who decades later develops primary lung adenocarcinoma within the prior radiation portal. Genomic profiling of the cancer demonstrated a KRAS G12V mutation. We briefly review the clinical entity of radiation-induced second malignancies and KRAS mutant lung adenocarcinoma. Although to date there is no standard molecularly targeted therapy available for KRAS mutant lung cancer, prior reports of activating EGFR mutations in a proportion of radiation-induced lung cancers suggest that a variety of genomic alterations may occur in these secondary malignancies. Given the potential to identify other molecularly defined subsets of lung cancer for which specific therapies exist, routine molecular profiling of these cases seems reasonable.

Original languageEnglish (US)
Pages (from-to)8-10
Number of pages3
JournalCancer Treatment Communications
Volume7
DOIs
StatePublished - 2016

Fingerprint

Radiation-Induced Neoplasms
Lung Neoplasms
Radiation
Mutation
Second Primary Neoplasms
Hodgkin Disease
Neoplasms
Therapeutics
Adenocarcinoma of lung

Keywords

  • Genomic alteration
  • Molecular profiling
  • Oncogene addiction
  • Secondary cancer
  • Thoracic
  • Toxicity

ASJC Scopus subject areas

  • Oncology

Cite this

@article{a82e6793cfbe4a65a9b69913c63d8cb1,
title = "Radiation-induced KRAS G12V mutant lung adenocarcinoma in a never smoker",
abstract = "The molecular profile of radiation-induced cancers remains poorly understood. This case report describes a 59-year-old male never smoker with a distant history of Hodgkin's lymphoma treated with mantle radiation who decades later develops primary lung adenocarcinoma within the prior radiation portal. Genomic profiling of the cancer demonstrated a KRAS G12V mutation. We briefly review the clinical entity of radiation-induced second malignancies and KRAS mutant lung adenocarcinoma. Although to date there is no standard molecularly targeted therapy available for KRAS mutant lung cancer, prior reports of activating EGFR mutations in a proportion of radiation-induced lung cancers suggest that a variety of genomic alterations may occur in these secondary malignancies. Given the potential to identify other molecularly defined subsets of lung cancer for which specific therapies exist, routine molecular profiling of these cases seems reasonable.",
keywords = "Genomic alteration, Molecular profiling, Oncogene addiction, Secondary cancer, Thoracic, Toxicity",
author = "Gibson, {Maeghan P.} and Joseph Sailors and Oliver, {Dwight H.} and Hak Choy and Gerber, {David E.}",
year = "2016",
doi = "10.1016/j.ctrc.2016.02.001",
language = "English (US)",
volume = "7",
pages = "8--10",
journal = "Cancer Treatment and Research Communications",
issn = "2213-0896",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Radiation-induced KRAS G12V mutant lung adenocarcinoma in a never smoker

AU - Gibson, Maeghan P.

AU - Sailors, Joseph

AU - Oliver, Dwight H.

AU - Choy, Hak

AU - Gerber, David E.

PY - 2016

Y1 - 2016

N2 - The molecular profile of radiation-induced cancers remains poorly understood. This case report describes a 59-year-old male never smoker with a distant history of Hodgkin's lymphoma treated with mantle radiation who decades later develops primary lung adenocarcinoma within the prior radiation portal. Genomic profiling of the cancer demonstrated a KRAS G12V mutation. We briefly review the clinical entity of radiation-induced second malignancies and KRAS mutant lung adenocarcinoma. Although to date there is no standard molecularly targeted therapy available for KRAS mutant lung cancer, prior reports of activating EGFR mutations in a proportion of radiation-induced lung cancers suggest that a variety of genomic alterations may occur in these secondary malignancies. Given the potential to identify other molecularly defined subsets of lung cancer for which specific therapies exist, routine molecular profiling of these cases seems reasonable.

AB - The molecular profile of radiation-induced cancers remains poorly understood. This case report describes a 59-year-old male never smoker with a distant history of Hodgkin's lymphoma treated with mantle radiation who decades later develops primary lung adenocarcinoma within the prior radiation portal. Genomic profiling of the cancer demonstrated a KRAS G12V mutation. We briefly review the clinical entity of radiation-induced second malignancies and KRAS mutant lung adenocarcinoma. Although to date there is no standard molecularly targeted therapy available for KRAS mutant lung cancer, prior reports of activating EGFR mutations in a proportion of radiation-induced lung cancers suggest that a variety of genomic alterations may occur in these secondary malignancies. Given the potential to identify other molecularly defined subsets of lung cancer for which specific therapies exist, routine molecular profiling of these cases seems reasonable.

KW - Genomic alteration

KW - Molecular profiling

KW - Oncogene addiction

KW - Secondary cancer

KW - Thoracic

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84959567365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959567365&partnerID=8YFLogxK

U2 - 10.1016/j.ctrc.2016.02.001

DO - 10.1016/j.ctrc.2016.02.001

M3 - Article

AN - SCOPUS:84959567365

VL - 7

SP - 8

EP - 10

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

SN - 2213-0896

ER -